Perrin Ngougni Pokem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Perrin Ngougni Pokem has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Françoise Van Bambeke
Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium
7 shared publications - Damien Gruson
Department of Laboratory Medicine, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium
4 shared publications - Gert-Jan Wijnant
Laboratory of Clinical Microbiology
3 shared publications - Olivier Cornu
Division of Orthopedics and Musculoskeletal Trauma, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
3 shared publications - Paul M. Tulkens
Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium
3 shared publications - Bénédicte Délire
Department of Hepato-Gastroenterology, Cliniques Universitaires Saint-Luc, UCLouvain, Avenue Hippocrate 10, B-1200 Brussels, Belgium
2 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Pharmacokinetic Modeling and Dosing Simulations of Temocillin in Children With Urinary Tract Infections
Background: Temocillin, active against most extended-spectrum β-lactamases (ESBL)-producing Enterobacterales , is increasingly considered a carbapenem-sparing option for Gram-negative infections. Despite a recommended pediatric dose of 25–50 mg/kg/d in 2 administrations, its pharmacokinetics in children remain ill characterized. This study aimed to characterize temocillin pharmacokinetics in young children with urinary tract infections using population pharmacokinetic modeling and to evaluate target attainment using Monte Carlo simulations. Methods: Eligible patients contributed 1–2 blood samples collected at different time points, providing coverage of the dosing interval through an ethically acceptable sparse sampling strategy. Total and unbound temocillin plasma concentrations were quantified using high-performance liquid chromatography–tandem mass spectrometry, and data were used for pharmacokinetic modeling. Probabilities of target attainment were calculated using Monte Carlo simulation. Results: Pediatric patients (6–34 months) hospitalized with urinary tract infection received temocillin at a dose of 25 mg/kg twice daily. Thirty unbound and 33 total plasma concentrations collected from 30 patients were available for analysis. A 1-compartment structural model including nonlinear protein binding was supported. Population pharmacokinetic estimates fell within the corresponding 95% confidence intervals and were consistent with bootstrap medians, supporting model stability. Clearance and volume of distribution were estimated at 2.81 L/h and 10.3 L, respectively. Interindividual variability of clearance was determined to be 21.2% in the population. Modeling predicted that the studied regimen would provide a >90% probability of target attainment against organisms with minimum inhibitory concentration (MIC) ≤2 mg/L when targeting 40% of the dosing interval with free-drug concentrations above the MIC (40% fT>MIC). Conclusion: Although sparse sampling limits parameter precision, characterization of interindividual variability, and covariate evaluation, these data may serve as an exploratory reference to inform preliminary dosing considerations in this pediatric population.
- 22 October 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Pharmacokinetic Modeling and Dosing Simulations of Temocillin in Children With Urinary Tract Infections
Background: Temocillin, active against most extended-spectrum β-lactamases (ESBL)-producing Enterobacterales , is increasingly considered a carbapenem-sparing option for Gram-negative infections. Despite a recommended pediatric dose of 25–50 mg/kg/d in 2 administrations, its pharmacokinetics in children remain ill characterized. This study aimed to characterize temocillin pharmacokinetics in young children with urinary tract infections using population pharmacokinetic modeling and to evaluate target attainment using Monte Carlo simulations. Methods: Eligible patients contributed 1–2 blood samples collected at different time points, providing coverage of the dosing interval through an ethically acceptable sparse sampling strategy. Total and unbound temocillin plasma concentrations were quantified using high-performance liquid chromatography–tandem mass spectrometry, and data were used for pharmacokinetic modeling. Probabilities of target attainment were calculated using Monte Carlo simulation. Results: Pediatric patients (6–34 months) hospitalized with urinary tract infection received temocillin at a dose of 25 mg/kg twice daily. Thirty unbound and 33 total plasma concentrations collected from 30 patients were available for analysis. A 1-compartment structural model including nonlinear protein binding was supported. Population pharmacokinetic estimates fell within the corresponding 95% confidence intervals and were consistent with bootstrap medians, supporting model stability. Clearance and volume of distribution were estimated at 2.81 L/h and 10.3 L, respectively. Interindividual variability of clearance was determined to be 21.2% in the population. Modeling predicted that the studied regimen would provide a >90% probability of target attainment against organisms with minimum inhibitory concentration (MIC) ≤2 mg/L when targeting 40% of the dosing interval with free-drug concentrations above the MIC (40% fT>MIC). Conclusion: Although sparse sampling limits parameter precision, characterization of interindividual variability, and covariate evaluation, these data may serve as an exploratory reference to inform preliminary dosing considerations in this pediatric population.
- Open Access
- 1 July 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0037226
A novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients
Meropenem is a valuable option for outpatient parenteral antimicrobial therapy (OPAT) due to its broad-spectrum activity, including multidrug-resistant Gram-negative bacteria, particularly when no oral alternatives exist. However, its conventional thrice-daily dosing poses logistical challenges for home administration, as the third dose typically falls during nighttime. This prospective pharmacokinetic study evaluated the adequacy of a novel daytime-only meropenem regimen adapted for OPAT in non-critically ill hospitalized patients. Twenty-two patients receiving meropenem 2 g every 8 h were switched, once clinically stable, to a thrice-daily, 6-hourly regimen compatible with daytime administration only. Meropenem was infused over 20 min. At steady state, unbound meropenem concentrations were measured for both regimens. These data informed a population pharmacokinetic model and Monte Carlo simulations to compare the probability of achieving predefined PK/PD targets. Both the conventional and OPAT-adapted regimens achieved a probability of target attainment (PTA) >90% for 40% f T >MIC at MIC ≤4 mg/L, exceeding the EUCAST/IDSA susceptibility breakpoint of 2 mg/L. Extending the infusion duration to 3 or 5 h with the OPAT-adapted schedule restored PTA >90% for MIC ≤8 mg/L. However, trough concentrations after the evening dose were lower with the OPAT-adapted regimen than with the standard regimen (1–2 vs 3–5 mg/L, depending on infusion duration). This may increase the risk of resistance selection despite the post-antibiotic effect of meropenem. With this caveat, OPAT regimens, with infusion duration adapted to MIC, may enable practical daytime-only meropenem administration, avoiding the need for overnight nursing visits.
- 1 July 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0037226
Open AccessA novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients
Meropenem is a valuable option for outpatient parenteral antimicrobial therapy (OPAT) due to its broad-spectrum activity, including multidrug-resistant Gram-negative bacteria, particularly when no oral alternatives exist. However, its conventional thrice-daily dosing poses logistical challenges for home administration, as the third dose typically falls during nighttime. This prospective pharmacokinetic study evaluated the adequacy of a novel daytime-only meropenem regimen adapted for OPAT in non-critically ill hospitalized patients. Twenty-two patients receiving meropenem 2 g every 8 h were switched, once clinically stable, to a thrice-daily, 6-hourly regimen compatible with daytime administration only. Meropenem was infused over 20 min. At steady state, unbound meropenem concentrations were measured for both regimens. These data informed a population pharmacokinetic model and Monte Carlo simulations to compare the probability of achieving predefined PK/PD targets. Both the conventional and OPAT-adapted regimens achieved a probability of target attainment (PTA) >90% for 40% f T >MIC at MIC ≤4 mg/L, exceeding the EUCAST/IDSA susceptibility breakpoint of 2 mg/L. Extending the infusion duration to 3 or 5 h with the OPAT-adapted schedule restored PTA >90% for MIC ≤8 mg/L. However, trough concentrations after the evening dose were lower with the OPAT-adapted regimen than with the standard regimen (1–2 vs 3–5 mg/L, depending on infusion duration). This may increase the risk of resistance selection despite the post-antibiotic effect of meropenem. With this caveat, OPAT regimens, with infusion duration adapted to MIC, may enable practical daytime-only meropenem administration, avoiding the need for overnight nursing visits.
- Open Access
- 1 June 2026
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 17 (3) , 190-196
Analytical Evaluation of a Point-of-Care Platform for Glycated Hemoglobin and N-Terminal Pro-B-Type Natriuretic Peptide Testing in Cardiometabolic Care
Background: Heart failure is a frequent complication of diabetes, highlighting the importance of integrated cardiometabolic assessment. Glycated hemoglobin (HbA1c) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) represent complementary biomarkers reflecting glycemic control and myocardial stress. Point-of-care testing (POCT) platforms may facilitate decentralized diagnostics and shorten analytical turnaround time. The aim of this study was to evaluate the analytical performance of the AFIAS-3 point-of-care fluorescence immunoassay platform for HbA1c and NT-proBNP measurements in comparison with established central laboratory methods. Methods: This single-center verification study included 50 patient samples for each analyte. HbA1c measurements obtained using AFIAS-3 were compared with Tosoh G8 high-performance liquid chromatography (HPLC), while NT-proBNP measurements were compared with the cobas 8000 electrochemiluminescence immunoassay. Analytical precision and accuracy were assessed using manufacturer quality control materials. Method comparison was performed using Passing–Bablok regression, Bland–Altman analysis, and Spearman correlation. Agreement at clinical thresholds was evaluated using Cohen’s kappa statistics. Results: For HbA1c, analytical precision was excellent, with coefficients of variation of 1.9% and 1.8%. Correlation with the reference method was strong (r = 0.98), and the mean bias was minimal (−0.03%). Agreement at the diagnostic threshold of 6.5% was excellent (κ = 0.92). For NT-proBNP, coefficients of variation were 5.3% and 15.4%. Correlation with the central laboratory method was very high (r = 0.99), although proportional bias was observed at higher concentrations (slope 1.24). Agreement at clinically relevant thresholds remained substantial. Conclusions: The AFIAS-3 POCT platform demonstrated excellent analytical agreement for HbA1c and acceptable agreement for NT-proBNP at clinically relevant thresholds. Dual biomarker POCT may support decentralized cardiometabolic diagnostics, although NT-proBNP values at higher concentrations should be interpreted cautiously.
- 1 June 2026
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 17 (3) , 190-196
Open AccessAnalytical Evaluation of a Point-of-Care Platform for Glycated Hemoglobin and N-Terminal Pro-B-Type Natriuretic Peptide Testing in Cardiometabolic Care
Background: Heart failure is a frequent complication of diabetes, highlighting the importance of integrated cardiometabolic assessment. Glycated hemoglobin (HbA1c) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) represent complementary biomarkers reflecting glycemic control and myocardial stress. Point-of-care testing (POCT) platforms may facilitate decentralized diagnostics and shorten analytical turnaround time. The aim of this study was to evaluate the analytical performance of the AFIAS-3 point-of-care fluorescence immunoassay platform for HbA1c and NT-proBNP measurements in comparison with established central laboratory methods. Methods: This single-center verification study included 50 patient samples for each analyte. HbA1c measurements obtained using AFIAS-3 were compared with Tosoh G8 high-performance liquid chromatography (HPLC), while NT-proBNP measurements were compared with the cobas 8000 electrochemiluminescence immunoassay. Analytical precision and accuracy were assessed using manufacturer quality control materials. Method comparison was performed using Passing–Bablok regression, Bland–Altman analysis, and Spearman correlation. Agreement at clinical thresholds was evaluated using Cohen’s kappa statistics. Results: For HbA1c, analytical precision was excellent, with coefficients of variation of 1.9% and 1.8%. Correlation with the reference method was strong (r = 0.98), and the mean bias was minimal (−0.03%). Agreement at the diagnostic threshold of 6.5% was excellent (κ = 0.92). For NT-proBNP, coefficients of variation were 5.3% and 15.4%. Correlation with the central laboratory method was very high (r = 0.99), although proportional bias was observed at higher concentrations (slope 1.24). Agreement at clinically relevant thresholds remained substantial. Conclusions: The AFIAS-3 POCT platform demonstrated excellent analytical agreement for HbA1c and acceptable agreement for NT-proBNP at clinically relevant thresholds. Dual biomarker POCT may support decentralized cardiometabolic diagnostics, although NT-proBNP values at higher concentrations should be interpreted cautiously.
- Open Access
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Ultra-rapid prolactin normalization with cabergoline in a premenopausal woman with epilepsy and giant prolactinoma
Giant prolactinomas are rare pituitary tumors characterized by extremely high prolactin levels and extensive extrasellar invasion. While dopamine agonists are usually effective, they may require months to normalize prolactin. We report a 47-year-old premenopausal woman presenting with new-onset temporal epilepsy and secondary amenorrhea. Assessments revealed marked hyperprolactinemia (mean serum prolactin concentration, 3902 ng/mL [SI: 169.8 nmol/L]) (reference range, 5.0-30.0 ng/mL [SI: 0.22-1.30 nmol/L]), and an invasive 47 × 43 × 50 mm adenoma extending into the right temporal lobe. After initiating cabergoline (0.25 mg/day), serum prolactin dropped to 802 ng/mL (SI: 34.9 nmol/L) within 18 hours and normalized by day 4 (12.7 ng/mL [SI: 0.55 nmol/L]). Polyethylene glycol recovery excluded macroprolactinemia. Despite ultra-rapid biochemical remission, magnetic resonance imaging at 3 and 6 months revealed no tumor shrinkage despite increasing cabergoline to a maximal tolerated dose of 0.75 mg/week. The patient remained seizure free and resumed normal menses. This case illustrates a striking dissociation between hormonal sensitivity and a lack of radiological regression.
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Open AccessUltra-rapid prolactin normalization with cabergoline in a premenopausal woman with epilepsy and giant prolactinoma
Giant prolactinomas are rare pituitary tumors characterized by extremely high prolactin levels and extensive extrasellar invasion. While dopamine agonists are usually effective, they may require months to normalize prolactin. We report a 47-year-old premenopausal woman presenting with new-onset temporal epilepsy and secondary amenorrhea. Assessments revealed marked hyperprolactinemia (mean serum prolactin concentration, 3902 ng/mL [SI: 169.8 nmol/L]) (reference range, 5.0-30.0 ng/mL [SI: 0.22-1.30 nmol/L]), and an invasive 47 × 43 × 50 mm adenoma extending into the right temporal lobe. After initiating cabergoline (0.25 mg/day), serum prolactin dropped to 802 ng/mL (SI: 34.9 nmol/L) within 18 hours and normalized by day 4 (12.7 ng/mL [SI: 0.55 nmol/L]). Polyethylene glycol recovery excluded macroprolactinemia. Despite ultra-rapid biochemical remission, magnetic resonance imaging at 3 and 6 months revealed no tumor shrinkage despite increasing cabergoline to a maximal tolerated dose of 0.75 mg/week. The patient remained seizure free and resumed normal menses. This case illustrates a striking dissociation between hormonal sensitivity and a lack of radiological regression.
- Open Access
- 28 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1882
Evaluation of a Ten-Antigen Immunodot Test in Autoimmune Hepatitis and Primary Biliary Cholangitis: Lessons Learned for a Tertiary Care Academic Hospital
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients who had never been diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice.
- 28 August 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1882
Open AccessEvaluation of a Ten-Antigen Immunodot Test in Autoimmune Hepatitis and Primary Biliary Cholangitis: Lessons Learned for a Tertiary Care Academic Hospital
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients who had never been diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice.
- 2 August 2024
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 787-804
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy
β-lactams are the most widely used antibiotics in children. Their optimal dosing is essential to maximize their efficacy, while minimizing the risk for toxicity and the further emergence of antimicrobial resistance. However, most β-lactams were developed and licensed long before regulatory changes mandated pharmacokinetic studies in children. As a result, pediatric dosing practices are poorly harmonized and off-label use remains common today. β-lactam pharmacokinetics and dose optimization strategies in pediatrics, including fixed dose regimens, therapeutic drug monitoring, and model-informed precision dosing are reviewed. Standard pediatric doses can result in subtherapeutic exposure and non-target attainment for specific patient subpopulations (neonates, critically ill children, e.g.). Such patients could benefit greatly from more individualized approaches to dose optimization, beyond a relatively simple dose adaptation based on weight, age or renal function. In this context, Therapeutic Drug Monitoring (TDM) and Model-Informed Precision Dosing (MIPD) emerge as particularly promising avenues. Obstacles to their implementation include the lack of strong evidence of clinical benefit due to the paucity of randomized clinical trials, of standardized assays for monitoring concentrations, or of adequate markers for renal function. The development of precision medicine tools is urgently needed to individualize therapy in vulnerable pediatric subpopulations.
- 2 August 2024
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 787-804
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy
β-lactams are the most widely used antibiotics in children. Their optimal dosing is essential to maximize their efficacy, while minimizing the risk for toxicity and the further emergence of antimicrobial resistance. However, most β-lactams were developed and licensed long before regulatory changes mandated pharmacokinetic studies in children. As a result, pediatric dosing practices are poorly harmonized and off-label use remains common today. β-lactam pharmacokinetics and dose optimization strategies in pediatrics, including fixed dose regimens, therapeutic drug monitoring, and model-informed precision dosing are reviewed. Standard pediatric doses can result in subtherapeutic exposure and non-target attainment for specific patient subpopulations (neonates, critically ill children, e.g.). Such patients could benefit greatly from more individualized approaches to dose optimization, beyond a relatively simple dose adaptation based on weight, age or renal function. In this context, Therapeutic Drug Monitoring (TDM) and Model-Informed Precision Dosing (MIPD) emerge as particularly promising avenues. Obstacles to their implementation include the lack of strong evidence of clinical benefit due to the paucity of randomized clinical trials, of standardized assays for monitoring concentrations, or of adequate markers for renal function. The development of precision medicine tools is urgently needed to individualize therapy in vulnerable pediatric subpopulations.
- Open Access
- 29 July 2024
- Published by MDPI AG in Preprints.org
Evaluation of a Ten Immunodot Antigens Test in Autoimmune Hepatitis and Primary Biliary Cholangitis, Lessons Learned for a Tertiary Care Academic Hospital
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients never diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice.
- 29 July 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of a Ten Immunodot Antigens Test in Autoimmune Hepatitis and Primary Biliary Cholangitis, Lessons Learned for a Tertiary Care Academic Hospital
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients never diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice.
- Open Access
- 4 March 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (3) , 236
The Microbiological Profile and Antibiotic Susceptibility of Fracture Related Infections in a Low Resource Setting Differ from High Resource Settings: A Cohort Study from Cameroon
Fracture-related infection (FRI) is a common and devastating complication of orthopedic trauma in all settings. Data on the microbiological profile and susceptibility of FRI to antibiotics in low-income countries are scarce. Therefore, this study aimed to investigate the microbial patterns and antimicrobial susceptibility of FRI in a sub-Saharan African setting in order to provide guidance for the formulation of evidence-based empirical antimicrobial regimens. We conducted a retrospective analysis of patients treated for FRI with deep tissue sampling for microbiological culture from January 2016 to August 2023 in four tertiary-level hospitals in Yaoundé, Cameroon. There were 246 infection episodes in 217 patients. Cultures were positive in 209 (84.9%) cases and polymicrobial in 109 (44.3%) cases. A total of 363 microorganisms from 71 different species were identified, of which 239 (65.8%) were Gram-negative. The most commonly isolated pathogens were Staphylococcus aureus (n = 69; 19%), Enterobacter cloacae (n = 43; 11.8%), Klebsiella pneumoniae (n = 35; 9.6%), Escherichia coli (n = 35; 9.6%), and Pseudomonas aeruginosa (n = 27; 7.4%). Coagulase-negative staphylococci (CoNS) were isolated in only 21 (5.9%) cases. Gram-negative bacteria accounted for the majority of the infections in early (70.9%) and delayed (73.2%) FRI, but Gram-positive bacteria were prevalent in late FRI (51.7%) (p < 0.001). Polymicrobial infections were more frequent in the early (55.9%) and delayed (41.9%) groups than in the late group (27.6%) (p < 0.001). Apart from Staphylococcus aureus, there was no significant difference in the proportions of causative pathogens between early, delayed, and late FRI. This study found striking resistance rates of bacteria to commonly used antibiotics. MRSA accounted for 63% of cases. The most effective antibiotics for all Gram-positive bacteria were linezolid (96.4%), vancomycin (92.5%), clindamycin (85.3%), and fucidic acid (89.4%). For Gram-negative bacteria, only three antibiotics displayed a sensitivity >50%: amikacin (80.4%), imipenem (74.4%), and piperacillin + tazobactam (57%). The most effective empirical antibiotic therapy (with local availability) was the combination of vancomycin and amikacin or vancomycin and imipenem. In contrast to the literature from high-resource settings, this study revealed that in a sub-Saharan African context, Gram-negative bacteria are the most common causative microorganisms of FRI. This study revealed striking resistance rates to commonly used antibiotics, which will require urgent action to prevent antimicrobial resistance in low and middle-income countries.
- 4 March 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (3) , 236
Open AccessThe Microbiological Profile and Antibiotic Susceptibility of Fracture Related Infections in a Low Resource Setting Differ from High Resource Settings: A Cohort Study from Cameroon
Fracture-related infection (FRI) is a common and devastating complication of orthopedic trauma in all settings. Data on the microbiological profile and susceptibility of FRI to antibiotics in low-income countries are scarce. Therefore, this study aimed to investigate the microbial patterns and antimicrobial susceptibility of FRI in a sub-Saharan African setting in order to provide guidance for the formulation of evidence-based empirical antimicrobial regimens. We conducted a retrospective analysis of patients treated for FRI with deep tissue sampling for microbiological culture from January 2016 to August 2023 in four tertiary-level hospitals in Yaoundé, Cameroon. There were 246 infection episodes in 217 patients. Cultures were positive in 209 (84.9%) cases and polymicrobial in 109 (44.3%) cases. A total of 363 microorganisms from 71 different species were identified, of which 239 (65.8%) were Gram-negative. The most commonly isolated pathogens were Staphylococcus aureus (n = 69; 19%), Enterobacter cloacae (n = 43; 11.8%), Klebsiella pneumoniae (n = 35; 9.6%), Escherichia coli (n = 35; 9.6%), and Pseudomonas aeruginosa (n = 27; 7.4%). Coagulase-negative staphylococci (CoNS) were isolated in only 21 (5.9%) cases. Gram-negative bacteria accounted for the majority of the infections in early (70.9%) and delayed (73.2%) FRI, but Gram-positive bacteria were prevalent in late FRI (51.7%) (p < 0.001). Polymicrobial infections were more frequent in the early (55.9%) and delayed (41.9%) groups than in the late group (27.6%) (p < 0.001). Apart from Staphylococcus aureus, there was no significant difference in the proportions of causative pathogens between early, delayed, and late FRI. This study found striking resistance rates of bacteria to commonly used antibiotics. MRSA accounted for 63% of cases. The most effective antibiotics for all Gram-positive bacteria were linezolid (96.4%), vancomycin (92.5%), clindamycin (85.3%), and fucidic acid (89.4%). For Gram-negative bacteria, only three antibiotics displayed a sensitivity >50%: amikacin (80.4%), imipenem (74.4%), and piperacillin + tazobactam (57%). The most effective empirical antibiotic therapy (with local availability) was the combination of vancomycin and amikacin or vancomycin and imipenem. In contrast to the literature from high-resource settings, this study revealed that in a sub-Saharan African context, Gram-negative bacteria are the most common causative microorganisms of FRI. This study revealed striking resistance rates to commonly used antibiotics, which will require urgent action to prevent antimicrobial resistance in low and middle-income countries.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2953. PK/PD Comparison of a New Dosing Scheme for Meropenem Adapted to Outpatient Parenteral Antimicrobial Therapy (OPAT) in Non-Critically-Ill Patients
Patients received first meropenem 2g q8h. At steady state ( > 3 doses), 4 blood samples were collected over 8h. The penultimate day of the treatment, patients were switched to the OPAT-compatible dosage regimen (2g q6h over 12h) and, at steady state, a total of 8 blood samples were collected during the first and third dosing intervals. Unbound meropenem concentrations were determined in ultrafiltrated plasma by a validated LC-MS/MS procedure. Time above MICs ≤ 8 mg/L (EUCAST susceptibility breakpoint) were estimated for both schemes based on PK profiles. Twenty-two patients were included. The mean pharmacokinetic profile for each scheme is shown in the Figure 1. The Table 1 shows that plasma concentrations remained > 4 mg/L during 100% time with the conventional scheme and > 2 mg/L with the OPAT-compatible scheme but still at least ∼80% time > 8 mg/L with both therapeutic schemes. Periods of inadequate coverage are spread at the end of each dose with the conventional dosing regimen but essentially concentrated overnight with the new scheme. PK/PD models recommend for meropenem therapeutic schemes with plasma concentrations > MIC during 30-40% of the time in non-critically ill patients. This target is easily achieved with the proposed OPAT-compatible dosing regimen, including during night, and could therefore be safely used in a context of limited nurse resources. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2953. PK/PD Comparison of a New Dosing Scheme for Meropenem Adapted to Outpatient Parenteral Antimicrobial Therapy (OPAT) in Non-Critically-Ill Patients
Patients received first meropenem 2g q8h. At steady state ( > 3 doses), 4 blood samples were collected over 8h. The penultimate day of the treatment, patients were switched to the OPAT-compatible dosage regimen (2g q6h over 12h) and, at steady state, a total of 8 blood samples were collected during the first and third dosing intervals. Unbound meropenem concentrations were determined in ultrafiltrated plasma by a validated LC-MS/MS procedure. Time above MICs ≤ 8 mg/L (EUCAST susceptibility breakpoint) were estimated for both schemes based on PK profiles. Twenty-two patients were included. The mean pharmacokinetic profile for each scheme is shown in the Figure 1. The Table 1 shows that plasma concentrations remained > 4 mg/L during 100% time with the conventional scheme and > 2 mg/L with the OPAT-compatible scheme but still at least ∼80% time > 8 mg/L with both therapeutic schemes. Periods of inadequate coverage are spread at the end of each dose with the conventional dosing regimen but essentially concentrated overnight with the new scheme. PK/PD models recommend for meropenem therapeutic schemes with plasma concentrations > MIC during 30-40% of the time in non-critically ill patients. This target is easily achieved with the proposed OPAT-compatible dosing regimen, including during night, and could therefore be safely used in a context of limited nurse resources. All Authors: No reported disclosures
- 26 August 2022
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (10) , 2742-2753
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications
Temocillin plasma protein binding (PPB) in healthy individuals is reported to be ∼85% but had not been studied in patients. To obtain normative data on temocillin PPB in patients in relation to infection and impact of co-medications widely used in ICU. Plasma was obtained from healthy individuals (Group #1), non-ICU patients with UTI (Group #2), ICU patients with suspected/confirmed ventriculitis (Group #3) or with sepsis/septic shock (Group #4). Total and unbound temocillin concentrations were measured in spiked samples from temocillin-naive donors (in vitro) or in plasma from temocillin-treated subjects (in vivo). The impact of diluting plasma, using pharmaceutical albumin, or adding drugs potentially competing for PPB was tested in spiked samples. Data were analysed using a modified Hill–Langmuir equation taking ligand depletion into account. Temocillin PPB was saturable in all groups, both in vitro and in vivo. Maximal binding capacity (Bmax) was 1.2–2-fold lower in patients. At 20 and 200 mg/L (total concentrations), the unbound fraction reached 12%–29%, 23%–42% and 32%–52% in Groups #2, #3, #4. The unbound fraction was inversely correlated with albumin and C-reactive protein concentrations. Binding to albumin was 2–3-fold lower than in plasma and non-saturable. Drugs with high PPB but active at lower molar concentrations than temocillin caused minimal displacement, while fluconazole (low PPB but similar plasma concentrations to temocillin) increased up to 2-fold its unbound fraction. Temocillin PPB is saturable, 2–4-fold lowered in infected patients in relation to disease severity (ICU admission, hypoalbuminaemia, inflammation) and only partially reproducible with albumin. Competition with other drugs must be considered for therapeutic concentrations to be meaningful.
- 26 August 2022
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (10) , 2742-2753
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications
Temocillin plasma protein binding (PPB) in healthy individuals is reported to be ∼85% but had not been studied in patients. To obtain normative data on temocillin PPB in patients in relation to infection and impact of co-medications widely used in ICU. Plasma was obtained from healthy individuals (Group #1), non-ICU patients with UTI (Group #2), ICU patients with suspected/confirmed ventriculitis (Group #3) or with sepsis/septic shock (Group #4). Total and unbound temocillin concentrations were measured in spiked samples from temocillin-naive donors (in vitro) or in plasma from temocillin-treated subjects (in vivo). The impact of diluting plasma, using pharmaceutical albumin, or adding drugs potentially competing for PPB was tested in spiked samples. Data were analysed using a modified Hill–Langmuir equation taking ligand depletion into account. Temocillin PPB was saturable in all groups, both in vitro and in vivo. Maximal binding capacity (Bmax) was 1.2–2-fold lower in patients. At 20 and 200 mg/L (total concentrations), the unbound fraction reached 12%–29%, 23%–42% and 32%–52% in Groups #2, #3, #4. The unbound fraction was inversely correlated with albumin and C-reactive protein concentrations. Binding to albumin was 2–3-fold lower than in plasma and non-saturable. Drugs with high PPB but active at lower molar concentrations than temocillin caused minimal displacement, while fluconazole (low PPB but similar plasma concentrations to temocillin) increased up to 2-fold its unbound fraction. Temocillin PPB is saturable, 2–4-fold lowered in infected patients in relation to disease severity (ICU admission, hypoalbuminaemia, inflammation) and only partially reproducible with albumin. Competition with other drugs must be considered for therapeutic concentrations to be meaningful.